bivamelagon

Small molecule

Also known as LB54640

Partialsignal

Evidence outlook · lead readout

NCT06046443 · Hypothalamic Obesity

The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.

NCT06046443: This was a randomized, triple-blind, placebo-controlled Phase 2 trial in 28 participants with hypothalamic obesity. All three LB54640 doses produced a statistically significant reduction in BMI at 14 weeks compared with placebo, for example the highest dose: -9.3% vs +2.2% with placebo, p=0.0004, meeting the trial primary comparison, though the very small number of participants limits how confidently this result generalizes.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Featured evidence outside this drug's tracked markets:NCT06040372 · Obese, Overweight, Healthy · Phase 1 · completed · Weak signal

Reported from a conference presentation covering 96 participants, fewer than the trial's registered enrollment; the source does not cite the trial's registry number. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Hypothalamic Obesity
Other / comorbidity
NCT06041841 · LG Chem
2023-12 – 2025-12 · POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity
What this study did
Phase 1 (1)
Other / comorbidity
NCT06040372 · LG Chem
2020-03-16 – 2022-07-30 · Obese, Overweight, Healthy
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Hypothalamic Obesity: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bivamelagon: this drugPhase 2Small moleculeMC4RPartial signal
NCT06046443: Mean % change in BMI at Week 14: 600mg -9.3% (p=0.0004), 400mg -7.7% (p=0.0002), 200mg -2.7% (p=0.0180), placebo +2.2%
Setmelanotide (Imcivree)ApprovedPeptideMC4RReliable signal
NCT05774756: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984)
Bremelanotide (Vyleesi)
Phase 2(overall; approved for another use)
PeptideMC4R
Reliable signal(overall)
No reviewed efficacy summary in this indication
RM-718
Phase 1/2(overall)
PeptideMC4R
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow bivamelagon to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
April 2028 (1)
Phase 2Hypothalamic ObesityEnrolling by invitation
Est. primary completion 2028-04-15 · NCT07156578 · CT.gov ↗
What to watch

See the full readout calendar ↗